Loading...
•
Jun 30, 2022
Coherus Q2 2022 Earnings Report
Coherus reported a decrease in revenue due to lower UDENYCA sales, but is preparing for multiple new product launches.
Key Takeaways
Coherus BioSciences reported a decrease in net revenue for Q2 2022, primarily due to lower sales of UDENYCA®. However, the company is preparing for the launch of multiple new products in 2022 and 2023, including CIMERLI™, toripalimab, and YUSIMRY™.
CIMERLI™ (ranibizumab-eqrn) was approved as a biosimilar product interchangeable with Lucentis®.
Commercial launch of CIMERLI™ is planned for early October 2022.
PDUFA date for toripalimab BLA is December 23, 2022.
Commercial preparation is underway for the planned July 2023 launch of YUSIMRY™.
Forward Guidance
Coherus is reducing the guidance range of combined 2022 R&D and SG&A expenses from $395 million to $430 million to a revised range of $375 million to $395 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...